MS is a progressive disease. While MS can present itself differently for each person, its underlying biology is similar for everyone. No matter what form of MS a person is diagnosed with, disease progression is present from the start.
MS is an immune-mediated disease of the central nervous system and the leading cause of non-traumatic disability in young adults, affecting people in the prime of their lives. Disease progression was once only associated with secondary progressive and primary progressive MS but is now recognised in relapsing remitting MS, even if a person is not experiencing relapses.
MS and disease progression can be a complicated topic to understand. As we gain a deeper understanding of disease progression and the different ways MS can present itself inside the body, we know that it’s a disease that can be managed and should be treated as early as possible.
Our ongoing research continues to advance our understanding of MS disease progression and what lies within the jungle of the brain.
There’s a symbiotic relationship between our understanding of MS and our tools for measuring it – better understanding leads to better tools, and better tools lead to a better understanding. We learn as we go, both in science and in the measurement of disease and its impact. At Roche we’re committed to advancing on both fronts.
30 MAY
International
Using martial artists as a metaphor, learn how B cells, important defenders within the immune system, play a central role in MS.
Watch this animation to help understand what disease progression really means in MS, its impact and how to manage it.
Jeanne shares her perspective on life with PPMS and the adaptions she has embraced to maintain her independence.
Jennifer shares her perspective on life with PPMS and how gives back to the MS community.
Understanding disability progression and the importance of supporting people to live their best lives.
Learn how the two types of inflammation in MS contributes to disease progression and how it can impact a person’s life.
Learn about underlying disease activity and ways to reduce future irreversible disability
Recent clinical evidence suggests that B cells contribute to both the inflammatory and neurodegenerative aspects of the disease.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.